PMID- 32448777
OWN - NLM
STAT- MEDLINE
DCOM- 20210812
LR  - 20210812
IS  - 1878-0938 (Electronic)
IS  - 1878-0938 (Linking)
VI  - 21
IP  - 12
DP  - 2020 Dec
TI  - Factors Associated With the Use of Bare Metal Stents in Patients With ST 
      Elevation Myocardial Infarction.
PG  - 1489-1492
LID - S1553-8389(20)30255-4 [pii]
LID - 10.1016/j.carrev.2020.05.008 [doi]
AB  - BACKGROUND: Drug eluting stents (DES) are used in the majority of patients 
      undergoing percutaneous coronary intervention (PCI). Factors associated with the 
      use of bare metal stents (BMS) for patients undergoing primary PCI for ST 
      elevation myocardial infarction (STEMI) have not been adequately explored. The 
      objective of this study was to evaluate factors associated with BMS use in STEMI 
      patients undergoing primary PCI. METHODS: Patients undergoing primary PCI for 
      STEMI between January 2008 and February 2015 were retrospectively identified. 
      Patients who received both a DES and BMS were included in the DES group and 
      patients receiving balloon angioplasty only were excluded. Baseline demographics, 
      angiographic variables, procedure related variables and in-hospital events were 
      collected. Multivariate analysis was performed to identify factors associated 
      with BMS use. RESULTS: Eight hundred and sixty-five patients underwent primary 
      PCI for STEMI during the study period. Seventy-two patients (8.3%) received 
      balloon angioplasty only and were excluded, yielding 793 patients for the study 
      cohort. Three hundred fifty-two patients (44%) received BMS and 441 patients 
      (56%) received DES. Patients receiving DES had a higher prevalence of diabetes 
      mellitus, prior myocardial infarction, prior PCI, left anterior descending artery 
      culprit location and Medicaid Insurance compared to those receiving BMS. Patients 
      receiving BMS had a higher prevalence of cardiogenic shock and right coronary 
      artery culprit location. Unadjusted in-hospital mortality was significantly 
      higher for patients receiving BMS compared to patients receiving DES, 11.1% vs 
      3.2%, respectively, p < 0.0001. Multivariate predictors of BMS use were 
      cardiogenic shock (OR 30.3; 95% CI 11.25 to 81.73) and diabetes mellitus (OR 
      2.99; 95% CI 1.04 to 8.64). CONCLUSION: In a contemporary series of patients 
      undergoing primary PCI for STEMI, BMS were used in 44% of patients and 
      independent factors associated with BMS use were cardiogenic shock and diabetes 
      mellitus.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Raj, Leah
AU  - Raj L
AD  - Division of Cardiovascular Medicine, University of Southern California, Los 
      Angeles, CA, United States of America.
FAU - Upadyhay, Rani
AU  - Upadyhay R
AD  - Division of Cardiovascular Medicine, University of Southern California, Los 
      Angeles, CA, United States of America.
FAU - Clavijo, Leonardo C
AU  - Clavijo LC
AD  - Division of Cardiovascular Medicine, University of Southern California, Los 
      Angeles, CA, United States of America.
FAU - Tun, Han
AU  - Tun H
AD  - Division of Cardiovascular Medicine, University of Southern California, Los 
      Angeles, CA, United States of America.
FAU - Mehra, Anilkumar
AU  - Mehra A
AD  - Division of Cardiovascular Medicine, University of Southern California, Los 
      Angeles, CA, United States of America.
FAU - Hindoyan, Antotreas
AU  - Hindoyan A
AD  - Division of Cardiovascular Medicine, University of Southern California, Los 
      Angeles, CA, United States of America.
FAU - Matthews, Ray V
AU  - Matthews RV
AD  - Division of Cardiovascular Medicine, University of Southern California, Los 
      Angeles, CA, United States of America.
FAU - Shavelle, David M
AU  - Shavelle DM
AD  - Division of Cardiovascular Medicine, University of Southern California, Los 
      Angeles, CA, United States of America. Electronic address: shavelle@usc.edu.
LA  - eng
PT  - Journal Article
DEP - 20200515
PL  - United States
TA  - Cardiovasc Revasc Med
JT  - Cardiovascular revascularization medicine : including molecular interventions
JID - 101238551
SB  - IM
MH  - Drug-Eluting Stents
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Retrospective Studies
MH  - *ST Elevation Myocardial Infarction
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Bare metal stent
OT  - Drug eluting stent
OT  - Dual antiplatelet therapy
OT  - Primary percutaneous coronary intervention
OT  - ST elevation myocardial infarction
EDAT- 2020/05/26 06:00
MHDA- 2021/08/13 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/03/22 00:00 [received]
PHST- 2020/04/22 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/08/13 06:00 [medline]
PHST- 2020/05/26 06:00 [entrez]
AID - S1553-8389(20)30255-4 [pii]
AID - 10.1016/j.carrev.2020.05.008 [doi]
PST - ppublish
SO  - Cardiovasc Revasc Med. 2020 Dec;21(12):1489-1492. doi: 
      10.1016/j.carrev.2020.05.008. Epub 2020 May 15.